Xu Wei

Summary

Country: China

Publications

  1. ncbi request reprint [Principle of adverse drug reaction causality judgement and interpretation of causality assessment method both in China and abroad]
    Xu Wei
    Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 37:2744-7. 2012
  2. ncbi request reprint [Influencing factor and mechanism analysis of adverse drug reaction in traditional Chinese medicine injection]
    Xu Wei
    Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 37:2748-51. 2012
  3. ncbi request reprint [Post-marketed re-evaluation of fleabane injection and Dengzhan Shengmai capsule study on treatment in patients with ischemic stroke]
    Xu Wei
    Institute of Basic Research in Clinical Trial, China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 36:2789-92. 2011
  4. ncbi request reprint [Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine]
    Xu Wei
    Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 36:2874-6. 2011
  5. ncbi request reprint [Skin test: guide of post-marketed re-evaluation of clinical safety in traditional Chinese medicine injection]
    Xu Wei
    Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 36:2877-9. 2011
  6. ncbi request reprint [Post-marketing re-evaluation of Kudiezi injection study on early treatment in patients with ischemic stroke]
    Xiaoqin Ye
    Post doctoral Station of China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 36:2793-5. 2011
  7. doi request reprint Population pharmacokinetics of naringin in total flavonoids of Drynaria fortunei (Kunze) J. Sm. in Chinese women with primary osteoporosis
    Jian Nong Wang
    Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100093, China
    Chin J Integr Med 18:925-33. 2012
  8. ncbi request reprint [Design requirements for clinical trials on re-evaluation of safety and efficacy of post-marketed Chinese herbs]
    Yanming Xie
    Institute of Basic Research in Clinical Basis Medicine, China Academy of Chinese Medical Science, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 36:2768-70. 2011

Collaborators

  • Qi Bi
  • Jun Jie Jiang
  • Yanming Xie
  • Jian Nong Wang
  • Xiaoqin Ye
  • Jian Peng Li
  • Xin Xiong
  • Jing li Duan
  • Yan Ming Xie
  • Danhui Yi
  • Yihuai Zou
  • Qingfan Xie
  • Zucheng Han
  • Yunzhi Ma
  • Xingquan Zhao
  • Shizhong Wang
  • Xiaolan Cao
  • Xinzhi Wang
  • Hongxia Chen
  • Yongyan Wang
  • Jianjun Zhao
  • Rongmei Yan
  • Jianhua Han

Detail Information

Publications8

  1. ncbi request reprint [Principle of adverse drug reaction causality judgement and interpretation of causality assessment method both in China and abroad]
    Xu Wei
    Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 37:2744-7. 2012
    ..There are some advantages and disadvantages among methods, but no causality assessment method can be applied to all ADR evaluation to date...
  2. ncbi request reprint [Influencing factor and mechanism analysis of adverse drug reaction in traditional Chinese medicine injection]
    Xu Wei
    Institute of Basic Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 37:2748-51. 2012
    ....
  3. ncbi request reprint [Post-marketed re-evaluation of fleabane injection and Dengzhan Shengmai capsule study on treatment in patients with ischemic stroke]
    Xu Wei
    Institute of Basic Research in Clinical Trial, China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 36:2789-92. 2011
    ..To verify the efficacy and safety of post-marketed fleabane injection combined with Dengzhan Shengmai capsules in the treatment of ischemic stroke (IS)...
  4. ncbi request reprint [Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine]
    Xu Wei
    Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 36:2874-6. 2011
    ..Its use depends on whether there is a safety problem for injection of TCM,and the determination of initial dose and sample size are key questions in study design...
  5. ncbi request reprint [Skin test: guide of post-marketed re-evaluation of clinical safety in traditional Chinese medicine injection]
    Xu Wei
    Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 36:2877-9. 2011
    ..Given the characteristics of type I allergy reaction,we should be pay close attention to skin test reaction in half an hour, and observation index need be designed based on post-marketed re-evaluation of clinical safety...
  6. ncbi request reprint [Post-marketing re-evaluation of Kudiezi injection study on early treatment in patients with ischemic stroke]
    Xiaoqin Ye
    Post doctoral Station of China Academy of Chinese Medical Sciences, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 36:2793-5. 2011
    ..To study the effect and safety of Kudiezi injection on patients with acute ischemic stroke...
  7. doi request reprint Population pharmacokinetics of naringin in total flavonoids of Drynaria fortunei (Kunze) J. Sm. in Chinese women with primary osteoporosis
    Jian Nong Wang
    Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100093, China
    Chin J Integr Med 18:925-33. 2012
    ..To evaluate the effect of covariates on the pharmacokinetic profiles of naringin in the total flavonoids of Drynaria fortunei (Kunze) J. Sm. in the Qianggu Capsule () by evaluating Chinese women with primary osteoporosis...
  8. ncbi request reprint [Design requirements for clinical trials on re-evaluation of safety and efficacy of post-marketed Chinese herbs]
    Yanming Xie
    Institute of Basic Research in Clinical Basis Medicine, China Academy of Chinese Medical Science, Beijing 100700, China
    Zhongguo Zhong Yao Za Zhi 36:2768-70. 2011
    ..Sample size needs to comply with statistical requirement. We commonly use cohort study, case-control study, nested case-control, pragmatic randomized controlled trials...